Hepatic Steatosis Clinical Trial
— SHAHOfficial title:
Hepatic Steatosis and Pituitary Gland Failure, Evaluation by NMR Imaging
| Verified date | February 2024 |
| Source | Centre Hospitalier Universitaire Dijon |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The investigator put forward the hypothesis that liver fat mass in patients with pituitary gland failure is greater than that in a control population. Failure of the anterior pituitary and more particularly impaired production of growth hormone (GH) could be the principal mechanism responsible for increased liver fat mass in these patients.
| Status | Completed |
| Enrollment | 21 |
| Est. completion date | October 10, 2015 |
| Est. primary completion date | October 10, 2015 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Patients who have provided consent - Patients over 18 years - Patients with pituitary disease (Pituitary adenoma, anterior pituitary failure, craniopharyngioma, empty sella syndrome, hypophysitis, infiltration of the stalk) requiring Magnetic Resonance Imaging (MRI) of the pituitary. Exclusion Criteria: - Persons without national health insurance - Pacemaker (Contra-Indication for MRI) - Alcohol consumption greater than 4 glasses a day - Any treatment able to increase liver fat content (glitazones, systemic corticoids, immunosuppressants) are forbidden - Presence of metallic implants (Contra-Indication for MRI) - Claustrophobia - Adult under guardianship - Pregnant or breast-feeding women - Patients with a liver disease other than non-alcoholic steatosis |
| Country | Name | City | State |
|---|---|---|---|
| France | CHU Dijon Bourgogne | Dijon |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Hospitalier Universitaire Dijon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Measurement of liver fat mass by Magnetic Resonance Imaging (MRI) | Measured at Day 0 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05480696 -
Soluble Fibre Supplementation in NAFLD
|
Phase 1 | |
| Completed |
NCT05124847 -
TREating Pediatric Obesity
|
N/A | |
| Recruiting |
NCT05499585 -
Treating Pediatric NAFLD With Nutrition
|
N/A | |
| Completed |
NCT03717935 -
Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS
|
N/A | |
| Active, not recruiting |
NCT02493153 -
Hepatic Steatosis After Cholecystectomy
|
N/A | |
| Active, not recruiting |
NCT05654051 -
The SLIM LIVER Study
|
Phase 2 | |
| Completed |
NCT03334214 -
Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT05599945 -
First Human Dose Trial for a New Medication to Potentially Treat Liver Diseases
|
Phase 1 | |
| Enrolling by invitation |
NCT02816814 -
Lacto-ovo-vegetarian Diet Riched in Omega-3 Fatty Acids in Menopausal Women
|
N/A | |
| Active, not recruiting |
NCT03587727 -
Hepatic Mitochondrial Function in Youth
|
||
| Not yet recruiting |
NCT05935826 -
Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)
|
N/A | |
| Not yet recruiting |
NCT06394206 -
Benefit of a Hospital Intervention in Patients With Hepatic Steatosis
|
N/A | |
| Not yet recruiting |
NCT06363617 -
Implementation of the Fatty Liver Index in Primary Care
|
N/A | |
| Recruiting |
NCT03142698 -
Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis
|
N/A | |
| Completed |
NCT00480922 -
Effects of a Low Glycemic Load Diet on Fatty Liver in Children
|
N/A | |
| Not yet recruiting |
NCT05871749 -
Effects of Hepatic Fibrosis on Hepatic Steatosis Using the Ultrasound Attenuation Imaging in Chronic Hepatitis B
|
||
| Recruiting |
NCT05897073 -
Time-Restricted Eating, Exercise and Cardiometabolic Health in Obesity
|
N/A | |
| Completed |
NCT03961516 -
Glycemic Characterization and Pancreatic Imaging Correlates in Cystic Fibrosis
|
||
| Completed |
NCT04180631 -
Quantitative US for Hepatic Steatosis
|
N/A | |
| Terminated |
NCT00845845 -
Fish Oil and Diet for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
|
Phase 2 |